A mechanism-based pharmacokinetic/pharmacodynamic analysis of polymyxin B-based combination therapy against carbapenem-resistant Klebsiella pneumoniae isolates with diverse phenotypic and genotypic resistance mechanisms.

doi:10.1128/aac.00782-25

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

A mechanism-based pharmacokinetic/pharmacodynamic analysis of polymyxin B-based combination therapy against carbapenem-resistant Klebsiella pneumoniae isolates with diverse phenotypic and genotypic resistance mechanisms.

Antimicrobial agents and chemotherapy - 4 Feb 2026

Mahadevan Ramya, Garcia Estefany, Sharma Rajnikant, Qiu Hongqiang, Elsheikh Ahmed, Parambi Robert, Abboud Cely Saad, Pasteran Fernando, Ramirez Maria Soledad, Kaye Keith S, Bonomo Robert A, Rao Gauri G

Abstract excerpt

Increased resistance to β-lactams/β-lactamase inhibitors by mutations in β-lactamase genes, porins, and efflux pumps complicates the management of carbapenem-resistant Klebsiella pneumoniae (CRKP). Polymyxin B (PMB)-based combination therapy is the best alternative treatment for middle and low-income countries that cannot access the latest medicines. It is crucial to know both phenotypic and genotypic...

Topics

Polymyxin B
Klebsiella pneumoniae
Anti-Bacterial Agents
Microbial Sensitivity Tests
Carbapenems
Drug Therapy, Combination
Porins
Humans
beta-Lactamases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Klebsiella Infections

Bacterial Proteins

Genotype

Meropenem

Mutation

Carbapenem-Resistant Enterobacteriaceae

Phenotype

Drug Resistance, Multiple, Bacterial

Source

Open in PubMed Open full text

Identifiers

PMID: 41416792
DOI: 10.1128/aac.00782-25
PMCID: PMC12888851

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A mechanism-based pharmacokinetic/pharmacodynamic analysis of polymyxin B-based combination therapy against carbapenem-resistant Klebsiella pneumoniae isolates with diverse phenotypic and genotypic resistance mechanisms.PMID 41416792Read ↗

A Mechanism Based Pharmacokinetic/Pharmacodynamic Analysis of Polymyxin B-Based Combination Therapy Against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Isolates with Diverse Phenotypic and Genotypic Resistance MechanismsSemantic proximity Read ↗

In vitro activity, pharmacodynamic profile and dose optimization of biapenem against NDM and OXA-48-like carbapenemase-producing Klebsiella pneumoniae: A multicentre study in Thailand.Semantic proximity Read ↗

Synergistic effects of polymyxin and vancomycin combinations on carbapenem- and polymyxin-resistant Klebsiella pneumoniae and their molecular characteristicsSemantic proximity Read ↗

Novel Approach To Optimize Synergistic Carbapenem-Aminoglycoside Combinations against Carbapenem-Resistant Acinetobacter baumanniiSemantic proximity Read ↗

Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design.Semantic proximity Read ↗

Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae.Semantic proximity Read ↗

Dynamic interaction of colistin and meropenem on a WT and a resistant strain ofPseudomonas aeruginosaas quantified in a PK/PD modelSemantic proximity Read ↗

Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.Semantic proximity Read ↗

Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniaeSemantic proximity Read ↗

Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.Semantic proximity Read ↗

Antimicrobial Activity Profiles and Potential Antimicrobial Regimens against Carbapenem-Resistant Enterobacterales Isolated from Multi-Centers in Western ThailandSemantic proximity Read ↗

In vivopharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteriaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.